Photo of Anchal Dhir

Partner in the General Corporate Practice at the Mumbai office of Cyril Amarchand Mangaldas. Anchal focuses on advising listed companies, their sponsors and investors on a broad range of issues that include M&A, corporate restructurings and securities laws. Given her extensive experience of advising various stakeholders in the listed space, Anchal is an integral part of the Firm’s corporate governance initiatives and advisory practice. She can be reached at  anchal.dhir@cyrilshroff.com.

The SEBI Board in its meeting held on June 25, 2020, has approved  providing listed companies with a time-bound temporary option of undertaking preferential allotments at a possibly more investment-friendly pricing, by choosing to utilise the higher of the two weeks or the 12 weeks formula price (i.e. based on the average of the weekly high and low of the volume weighted average price quoted on the stock exchange – the pricing formula) instead of the existing norm of higher of the two weeks or the 26 weeks formula price. Given the current market conditions, which has seen a significant stock price drop since the second half of March, 2020, this option is bound to result in lower and arguably more favourable pricing for potential investments.


Continue Reading New Pricing for Preferential Allotments: Getting on the Funding Train

DISCLOSURE OF COVID-19 IMPACT BY LISTED ENTITIES - FINDING THE RIGHT BALANCE

Across India, each subsequent phase of the lockdown has permitted a responsible increase in economic activity. As companies re-start their operations, they continue to assess the impact of Covid-19 pandemic on their businesses and operations, which is rapidly and continuously evolving. Listed entities are particularly conscious of their disclosure obligations, more so after the Securities and Exchange Board of India (“SEBI”) issued a circular on May 20, 2020 (the “Circular”), that outlined the relevant considerations for companies in relation to the disclosures on the impact of Covid-19 on their businesses, performance and financials. The Circular is not only a restatement of the current principle-based disclosure regime, but is also indicative of the regulatory expectation on disclosures going forward in relation to impact of Covid-19 pandemic as it evolves.
Continue Reading Disclosure of Covid-19 Impact by Listed Entities – Finding the Right Balance